Several brokerages have updated their recommendations and price targets on shares of BioMarin Pharmaceutical (NASDAQ: BMRN) in the last few weeks:

  • 8/9/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $119.00 price target on the stock, up previously from $118.00.
  • 8/7/2017 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $108.00 price target on the stock.
  • 8/4/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Cowen and Company.
  • 8/4/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $107.00 price target on the stock.
  • 8/3/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $119.00 price target on the stock, up previously from $118.00.
  • 8/3/2017 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by analysts at UBS AG. They now have a $93.00 price target on the stock, up previously from $92.00.
  • 7/27/2017 – BioMarin Pharmaceutical is now covered by analysts at Sanford C. Bernstein. They set a “market perform” rating and a $89.00 price target on the stock.
  • 7/24/2017 – BioMarin Pharmaceutical was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/22/2017 – BioMarin Pharmaceutical had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $100.00 price target on the stock, down previously from $105.00.
  • 7/19/2017 – BioMarin Pharmaceutical was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “BioMarin’s orphan disease drugs – Vimizim and Kuvan – are doing well, backed by strong underlying patient demand trends. BioMarin should continue to see growth in both the drugs in 2017, driven by robust patient growth and penetration.  Brineura’s FDA and EU approval was a huge boost. Pipeline development is also on track with significant upcoming pipeline news flow. However, BioMarin has suffered few regulatory setbacks related to its pipeline candidates in the past. Delayed approvals or further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due infrequent ordering patterns from some countries. Meanwhile, the stock underperformed the broader industry this year so far. Loss estimates have remained stable ahead of the company’s Q2 earnings result. However, BioMarin has a positive record of earnings surprises in the recent quarters.”
  • 7/18/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Leerink Swann.
  • 7/17/2017 – BioMarin Pharmaceutical was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 7/17/2017 – BioMarin Pharmaceutical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $105.00 price target on the stock. According to Zacks, “BioMarin’s orphan disease drugs – Vimizim and Kuvan – are doing well, backed by strong underlying patient demand trends. BioMarin should continue to see growth in both the drugs in 2017, driven by robust patient growth and penetration. Brineura’s FDA and EU approval was a huge boost for BioMarin. Pipeline development is also on track with significant upcoming pipeline news flow. Meanwhile, the stock outperformed the broader industry this year so far. However, BioMarin has suffered few regulatory setbacks related to its pipeline candidates in the past. Delayed approvals or further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due infrequent ordering patterns from some countries. Loss estimates have remained stable ahead of Q2 earnings result. However, BioMarin has a positive record of earnings surprises in the recent quarters.”
  • 7/14/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $115.00 price target on the stock.
  • 7/13/2017 – BioMarin Pharmaceutical had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $115.00 price target on the stock, up previously from $111.00.
  • 7/11/2017 – BioMarin Pharmaceutical had its “buy” rating reaffirmed by analysts at Cowen and Company. They wrote, “New data include 52 wk follow-up on all patients at BMN270’s 6e13 vg/kg dose, and.””
  • 6/15/2017 – BioMarin Pharmaceutical was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ BMRN) traded down 3.76% during mid-day trading on Thursday, hitting $81.96. The company’s stock had a trading volume of 1,637,420 shares. The company’s market cap is $14.36 billion. The stock’s 50 day moving average price is $89.90 and its 200 day moving average price is $90.05. BioMarin Pharmaceutical Inc. has a 52-week low of $78.42 and a 52-week high of $102.06.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. The firm had revenue of $317.50 million for the quarter, compared to the consensus estimate of $311.41 million. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the business posted ($2.61) EPS. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post ($0.71) EPS for the current year.

In other news, Director V Bryan Lawlis sold 3,750 shares of the firm’s stock in a transaction on Friday, June 16th. The stock was sold at an average price of $90.00, for a total value of $337,500.00. Following the transaction, the director now directly owns 19,660 shares in the company, valued at approximately $1,769,400. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP George Eric Davis sold 9,844 shares of the firm’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $96.60, for a total value of $950,930.40. Following the completion of the transaction, the executive vice president now owns 93,425 shares in the company, valued at $9,024,855. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 61,740 shares of company stock worth $5,659,589. Company insiders own 2.50% of the company’s stock.

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Receive News & Ratings for BioMarin Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.